EmailLast evening, Kodiak Sciences (KOD) priced its 9 mln
share IPO at $10 per share, below the expected $13-$15 range. The stock opened for trading on the Nasdaq earlier today at $10.00.
Based in California, Kodiak Sciences is a clinical stage
biopharmaceutical company that specializes in novel therapies aimed at treating
chronic, high-prevalence retinal diseases.
The company's lead product candidate -- KSI-301 -- is a biologic
therapy designed to maintain potent and effective drug levels in ocular tissue.
The company believes that the product candidate has the potential to become a
significant therapy method for wet age-related macular degeneration (wet AMD)
and diabetic retinopathy. The company owns worldwide rights to the development
platform.
The company has used its platform to develop other product
candidates, like KSI-501, which is a bispecific anti-IL-6/VEGF bioconjugate. Kodiak
Sciences plans to continue developing other product candidates to address
high-prevalence ophthalmic diseases.
The company initiated a Phase 1 clinical study of KSI-301 in
nine patients in July 2018. All patients enrolled were dosed successfully,
reaching the primary safety and tolerability endpoints of the study. Patients
have not reported any significant adverse events. The company observed
improvements in best corrected visual acuity and reductions in macular
thickness at all dose levels. Overall, the study suggests that KSI-301 is
biologically active at all dose levels.
The company expects to begin a Phase 2 study of KSI-301 in
early 2019. Approximately 400 patients will take part in the randomized study,
which will evaluate the impact of different dosing schedules and versus Regneron
Pharma’s (REGN) EYLEA (aflibercept). The study will be run in the U.S., and the
company also plans to initiate one Phase 2 study in the European Union and two
Phase 2 studies in China.
Kodiak Sciences believes its success will depend on the
completion of the development of KSI-301 and broadening the use to other
conditions. The company also hopes to advance the development of its other
product candidates.
The company plans to use $40 mln of IPO proceeds to advance
KSI-301 though Phase 2 trials in the U.S. and the European Union in patients
with wet age-related macular degeneration. Another $25 mln will be used to
advance KSI-301 into Phase 2 clinical trials in China. The company plans to
spend $15 mln to advance KSI-301 into global Phase 2 clinical trials in
patients with diabetic retinopathy while another $15 mln will be spent on
research and development of the company's pipeline. Remaining funds will be
used for working capital and other general corporate purposes.
The company has no history of revenue generation. During the
six months ended June 30, the company spent $7.23 mln on research and
development, down 28.4% from $10.10 mln spent during the first six months of
2017. The company's loss from operations totaled $10.64 mln during the first
six months of 2018, an improvement of 9.7% from the $11.79 mln lost during the first six months
of 2017.
Kodiak Sciences had $17.64 mln in cash and cash equivalents
at the end of the first half of 2018.
than one year.
The Briefing.com RSS (really simple syndication) service is a method by which we offer story headline feeds in XML format to readers of the Briefing.com web site who use RSS aggregators. By using Briefing.com’s RSS service you agree to be bound by these Terms of Use. If you do not agree to the terms and conditions contained in these Terms of Use, we do not consent to provide you with an RSS feed and you should not make use of Briefing.com’s RSS service. The use of the RSS service is also subject to the terms and conditions of the Briefing.com Reader Agreement which governs the use of Briefing.com's entire web site (www.briefing.com) including all information services. These Terms of Use and the Briefing.com Reader Agreement may be changed by Briefing.com at any time without notice.
Use of RSS Feeds:
The Briefing.com RSS service is provided free of charge for
use by individuals, as long as the feeds are used for such individual’s
personal, non-commercial use. Any other uses, including without
limitation the incorporation of advertising into or the placement
of advertising associated with or targeted towards the RSS Content,
are strictly prohibited. You are required to use the RSS feeds
as provided by Briefing.com and you may not edit or modify the
text, content or links supplied by Briefing.com. To acquire
more extensive licensing rights to Briefing.com content please
review this page.
Link to Content Pages:
The RSS service may be used only with those platforms from which
a functional link is made available that, when accessed, takes
the viewer directly to the display of the full article on the
Briefing.com web site. You may not display the RSS content in
a manner that does not permit successful linking to, redirection
to or delivery of the applicable Briefing.com web site page.
You may not insert any intermediate page, “splash” page or any
other content between the RSS link and the applicable Briefing.com
web site page.
Ownership/Attribution:
Briefing.com retains all ownership and other rights in the RSS
content, and any and all Briefing.com logos and trademarks used
in connection with the RSS service. You are required to provide
appropriate attribution to the Briefing.com web site in connection
with your use of the RSS feeds. If you provide this attribution
using a graphic we require you to use the Briefing.com web site
logo that we have incorporated into the Briefing.com RSS feed.
Right to Discontinue Feeds:
Briefing.com reserves the right to discontinue providing any
or all of the RSS feeds at any time and to require you to cease
displaying, distributing or otherwise using any or all of the
RSS feeds for any reason including, without limitation, your
violation of any provision of these Terms of Use or the terms
and conditions of the Briefing.com Reader Agreement. Briefing.com
assumes no liability for any of your activities in connection
with the RSS feeds or for your use of the RSS feeds in connection
with your web site.
